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Editor’s key points
† Patient-controlled
remifentanil boluses may
have a role in the
management of labour
pain.
† Ideally, peak levels of
remifentanil should
coincide with maximum
uterine contractions.
† This study used
quantifying contraction
strength to improve
modelling of remifentanil
concentrations.
† It was not possible to
coordinate peak
remifentanil
concentrations with
contraction strength.
† Safe use of remifentanil
boluses in obstetric pain
management will still
require careful clinical
monitoring.
Background. The safetyof patient-controlled i.v. analgesia (PCA) with remifentanil forobstetrical
analgesia remains a matter of concern. The efficacy of remifentanil bolus application, that is, the
coincidence between pain and remifentanil effect-site concentration, may be improved by
forecasting contractions, but it is not known whether such a technique would also improve
safety.
Methods. We recorded pain intensity during labour continuously using a handheld
dynamometer in 43 parturients. Using these data, we compared different models in their
ability to predict future contractions. In addition, we modelled remifentanil effect-site
concentration using three simulated modes of bolus administration, with and without
prediction of future contractions.
Results. The average duration of pain during contractions recorded by the dynamometer was
45 [14 standard deviation (SD)] s. The time interval between painful contractions was highly
variable, with a mean of 151 (31 SD) s during the first and 154 (52 SD) s during the second
recording. Using a simple algorithm (three-point moving average), the SD of the difference
between predicted and observed inter-contraction intervals can be reduced from 0.95 to
0.79 min. However, the coincidence between remifentanil concentration and pain during
contraction is not substantially improved when using these models to guide remifentanil
bolus application.
Conclusions. Because of the large variability of inter-contraction intervals, the use of
prediction models will not influence the mean remifentanil concentration in-between
contractions. Using models predicting future contractions to improve the timing of
remifentanil PCA bolus administration will not diminish the need of continuous clinical
surveillance and other safety measures.
Keywords: analgesia, obstetrical; analgesia, patient-controlled; forecasting;
pharmacokinetics; remifentanil; safety
Accepted for publication: 18 August 2014
The use of remifentanil for analgesia during labour has
become increasingly popular in recent years.1 – 3 However, as
documented by several case reports,4 – 7 serious side-effects
do exist, and therefore, studies looking at the optimization of
the efficacy and safety of remifentanil patient-controlled
analgesia (PCA) during labour are needed.
In theory, the efficacy of remifentanil application during
labour will be determined by the effect-site concentration of
remifentanil reached during a contraction. An optimal effect
would be achieved if the remifentanil concentration is suffi-
ciently high to be effectivelyanalgesic during the total duration
of pain during acontraction. On thecontrary, the safetyof remi-
fentanil use during labour will be theoretically determined by
the remifentanil effect-site concentration in-between two
painful contractions, inducing respiratory depression. Thus,
an optimal remifentanil application during labour would
achieve high (‘effective’) remifentanil concentrations during
each painful contraction and low (‘safe’) concentrations in
between painful contractions.
With standard PCA systems, a bolus is demanded by the par-
turient at the beginning of the pain felt with a contraction. This
way, peak remifentanil concentration will not be optimally
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timed. At the beginning of the painful contraction, remifentanil
concentration is still insufficient to alleviate the pain, whereas
it will be still high after the end of the pain, inducing respiratory
depression. Several attempts have already been made to
improve the use of remifentanil during labour by modifying
the bolus application8 9 or forecasting future contractions.10
The latter solution appears to be promising, since a remifenta-
nil bolus may be delivered just before the beginning of a con-
traction, allowing peak remifentanil concentration to
coincide with peak pain during the contraction.
To our knowledge, no study has until now attempted to
compare the timing of pain during contractions and the remi-
fentanil concentrations achieved with either standard bolus
application at the beginning of the pain sensation or with opti-
mized bolus delivery by prediction before the start of a contrac-
tion. Such a comparison would allow a better understanding of
efficacy and safety of remifentanil use during labour.
Our study included an experimental part (clinical observa-
tion in the labour ward) and a mathematical modelling part.
The study had three objectives. First, we aimed to record the
timing and duration of pain during contractions using a new
approach consisting of handgrip force measured bya handheld
dynamometer (first part). In the second part of the study, we
used these data to simulate time series of (painful) contrac-
tions and also remifentanil concentrations achieved with
either standard bolus application at the beginning of the pain
sensation or with optimized bolus delivery by prediction of
the contractions. The objective of optimization is to find an
optimum coincidence of remifentanil concentration and the
intensity of pain during uterine contractions.
Finally, different models of prediction of future contractions
were compared and the most parsimonious chosen for further
evaluation of efficacy and safety of a hypothetical optimized
remifentanil PCA application system during labour.
Methods
After institutional review board approval (Commission centrale
d’e´thique de la recherche sur l’eˆtre humain des HUG 12-077)
and written informed consent, 43 parturients were included
in the study. Parturients received information about the study
on arrival in the delivery suite.
Experimental part of the study
After informed consent, the handling of the dynamometer was
explained and reference values for handgrip force correspond-
ing to subjective pain levels of moderate pain (5 on a scale of
0–10) and extreme pain (10 on a scale of 0–10) were obtained.
The dynamometer (Noraxon Biofeedback dynamometer,
Velamed, Cologne, Germany) was connected via an analogue–
digital interface to a portable computer. Handgrip force
measured by the dynamometer was recorded continuously
using Signal software (CED, Cambridge, UK) during periods of
20 min each. Women were instructed to compress the dyna-
mometer with a force corresponding to their subjective pain
level and hold it until the pain has subsided. In parallel, the ex-
ternal tocographic signal of uterine contractions and an ab-
dominal wall electromyogram were recorded.
The first recording (20 min) of frequency and intensity of
contractions was taken during the first stage of labour when
women experienced regular painful contractions, not yet re-
quiring analgesia except for physical relaxation techniques
provided by the midwife.
A second recording of 20 min duration was obtained during
more advanced labour at the time when women demanded
epidural analgesia, but before epidural placement. There was
no minimal cervical dilation for epidural analgesia and there-
fore, the time during labour for the second recording was
variable, from early to late first stage of labour.
Analysis
The duration of the pain during contractions was measured as
the time for which the dynamometer signal deviated from
baseline, indicating pain. The interval between painful contrac-
tions was measured as the time between two starting points of
the deviation from baseline on the dynamometer signal. These
durations and intervals were compared with those recorded
by external tocography.
Mathematical modelling
Modelling of contraction time series
Time series of duration and intervals of painful contractions
obtained from the dynamometer signal were further analysed
using the R statistical software.11 Let di be the contraction
interval between contraction i–1 and i and knowing the first
contraction interval, we are trying to forecast with an horizon
of 1 the next contraction interval:
di+1 = V(d0, . . . , di)
The simplest way to forecast the next interval is to use the
previous one (‘naı¨ve’ forecasting):
di+1 = di.
Another simple wayof forecasting is to use a moving average of
the lastn contraction intervals. Here, we usedn¼2–4, because
sample calculations with higher n did not improve forecasting.
More elaborate forecasting methods are exponential
smoothing (ETS) and the autoregressive integrated moving
average (ARIMA), both available as functions of the R forecast
package.11 The functions were used to provide automatic
adaptation of all parameters and choice of an optimized
model based on maximum likelihood estimation and Akaike’s
information criterion.12 For each new contraction, a new
optimal model was computed with both ETS and ARIMA and
then used to forecast the next contraction interval.
To obtain longer time series to test the different prediction
models, inter-contraction time interval data of at least 100
min duration derived from external tocography monitoring
from an additional 25 parturients were used.
Modelling of remifentanil concentration
Remifentanil effect-site concentrations were modelled using
STANPUMP (Steven Shafer, Stanford, available at www.
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opentci.org) and the model published by Minto and collea-
gues.13 Simulations are based on a typical patient, 25 yr old,
with a height of 165 cm, and a weight of 70 kg. Bolus dose
was 35 mg (0.5 mg kg21), and the bolus was assumed to be
delivered within 10 s. Bolus doses vary widely in the literature,
the dose chosen was the mean dose of the studies included in
the systematic review of Schnabel and colleagues.3
The average effect-site concentration of remifentanil during
contractions was used as an estimate of PCA efficacy, and the
average effect-site concentration in the inter-contraction
interval was used as an estimate of PCA safety.
Comparison of the models predicting contractions
For each labour data set, we computed the prediction error
defined as the difference xi between the exact delay between
two consecutive contractions and the predicted counterpart
using a method M. For every forecasting method used, the
error is normally distributed with mean E(x)¼0. We were inter-
ested to find the method M which would give the smallest
standard deviation (SD) of the prediction error, meaning that
on average, the prediction by M is the most accurate. Since
XM is normally distributed over zero with variance sM, we use
a Bartlett’s test to verify homoscedasticity for the different
forecasting methods. For the Bartlett’s test, the null hypothesis
is that there is no difference in prediction variance whatever
the forecasting method is, thus a significant P-value indicates
that there are at least two variances that are significantly
different.
Results
The 43 participating women had an average age of 32 (4 SD) yr,
weighed on average 75 (11 SD) kg, and had an average height of
164 (5 SD) cm, resulting in an average BMI of 28 kg m22 (4 SD).
Two-thirds of the women were nulliparous, and one-third
had induced labour. In two-thirds of the women, cervical dila-
tation was still less than 20 mm when the second recording of
pain during contractions was performed (at our institution,
most women demand and receive epidural analgesia early
during labour). An original tracing of the dynamometer is
shown in Figure 1. As reported elsewhere, hand grip force
recorded by the dynamometer was moderately correlated
with subjective pain intensity.14 Pain during contractions
recorded via the dynamometer corresponded well with those
on the tocographic tracing and onset of pain coincides with
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Fig 1 Original tracings of the handheld dynamometer for an exemplary parturient (continuous line) in parallel with the external tocography
recording (dashed line). Handgrip force is given in newtons and time in seconds. The baseline limit (dotted line) is determined byaveraging baseline
fluctuations of the dynamometer signal.
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the onset of contractions. However, the duration of pain during
the contractions was shorter than the duration of the rise in ab-
dominal wall tension for most contractions. The average dur-
ation of pain during contractions recorded by the
dynamometer was 45 s both during the first and the second
recording, with an SD of 14 s.
The time interval between painful contractions was highly
variable, with a mean of 151 (31 SD) s during the first and 154
(52 SD) s during the second recording. Examples of time series
data (four patients with the longest time series of more than
200 min) of the inter-contraction time interval are shown in
Figure 2.
Using the time series of the inter-contraction time intervals,
different models were tested in their ability to predict future
contractions.
Prediction of future contractions by modelling
contraction time series
The ‘goodness of fit’ of the different models can be described by
the differences between predicted values and actual values or
rather the SD of these differences, since the differences them-
selves will have a standard distribution with a mean of zero.
In Table 1, the SDs of these differences are shown for all
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Fig 2 Time series data of the inter-contraction time interval from four patients (coded t2, t4, t6, t25) with uninterrupted time series of more than
200 min.
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models and each of the 24 patients with long (.100 min) time
series. For eight of the 24 cases, a Bartlett’s test for
equal variances yielded a significant difference between
models (Table 1). Differences between simple moving average
forecasting models (at least with means of ≥3) and the more
elaborate ETS and ARIMA models are negligible.
A simple three-point moving average model was thus con-
sidered a parsimonious compromise between forecasting effi-
cacy and complexity (which coincides with computationally
demanding calculation) and used for further calculations.
Modelling of remifentanil effect-site concentration
Using the average duration of pain during contractions and the
inter-contraction intervals obtained by the dynamometer
recordings, remifentanil effect-site concentration was mod-
elled in relation to the timing of pain during the contractions.
To simplify modelling, the duration of pain during contractions
was modelled as fixed, using the mean duration obtained from
the dynamometer recordings.
Figure 3 shows, for one patient, the remifentanil plasma
and effect-site concentrations when the remifentanil bolus is
administered at the beginning of the pain sensation (Fig. 3A),
in an ideal situation where remifentanil concentration is
optimized to coincide with the pain sensation (Fig. 3B), and
when automatically administered using a three-point moving
average prediction algorithm (Fig. 3C). Although the prediction
algorithm improves correlation of pain duration and remifen-
tanil effect-site concentration, sometimes the model predicts
a contraction which does not occur (arrows in Fig. 3).
For most patients, the efficacy of a remifentanil PCA, mea-
sured as the average remifentanil concentration during a
contraction (and the ‘instantaneous’ concentration at the be-
ginning of the pain sensation during contractions), can be
improved when using an optimized timing by a simple three-
point moving average forecast of contractions (Fig. 4).
Themeanconcentrationofremifentanil in-betweentwocon-
tractions, however, which is a factor of the safetyof a remifenta-
nil PCA, is less changed when bolus timing is optimized (Fig. 4).
Discussion
The experimental part of this study provides data about the
timing, duration, and spacing of pain during the first stage of
labour, and about its regularity or rather irregularity. A study
of a large cardiotocography database has found similar
values for the intervals in between contractions,15 obviously
without giving information about pain duration and, more
Table1 SDs (in min) of the differences between observed and predicted inter-contraction intervals for all patients with long (.100 min) time series
and the different forecast models: naı¨ve, moving average (mean) of the last 2, 3, and 4 intervals, ETS, and autoregressive integrated moving average
(ARIMA). P-values are given for Bartlett’s test to check for equal variances between different models (null hypothesis—no differences between the
variances for all models)
Patient Naı¨ve Mean 2 Mean 3 Mean 4 ETS ARIMA P-value
1 1.70 1.64 1.63 1.74 1.86 1.74 0.65
2 1.00 1.00 0.98 0.98 0.93 0.97 0.91
3 0.69 0.61 0.57 0.54 0.55 0.54 0.17
4 0.81 0.67 0.62 0.60 0.56 0.54 0.00
5 0.52 0.49 0.49 0.51 0.51 0.53 0.91
6 0.88 0.79 0.78 0.79 0.82 0.80 0.77
7 1.23 0.90 0.92 0.88 0.87 0.85 0.01
8 0.74 0.66 0.62 0.57 0.61 0.59 0.51
9 0.89 0.74 0.77 0.70 0.65 0.63 0.62
10 1.22 1.11 0.97 0.94 0.91 0.86 0.03
11 1.54 1.51 1.34 1.31 1.20 1.21 0.47
12 1.44 1.14 1.10 1.05 1.03 0.98 0.05
13 1.74 1.50 1.48 1.48 1.62 1.65 0.72
14 0.43 0.36 0.36 0.36 0.38 0.39 0.14
15 0.48 0.42 0.39 0.37 0.37 0.36 0.01
16 1.01 0.83 0.77 0.75 0.74 0.68 0.02
17 0.42 0.37 0.34 0.33 0.34 0.33 0.26
18 0.66 0.52 0.50 0.49 0.46 0.44 0.01
19 0.73 0.59 0.55 0.56 0.55 0.56 0.20
20 1.24 1.05 1.05 1.02 1.15 1.11 0.47
21 0.68 0.64 0.59 0.55 0.51 0.51 0.01
22 0.69 0.64 0.55 0.55 0.59 0.54 0.11
23 0.66 0.59 0.52 0.52 0.52 0.62 0.04
24 1.36 1.08 1.05 1.01 1.00 1.04 0.03
Average 0.95 0.83 0.79 0.77 0.78 0.77
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importantly, about the irregularity of individual time series of
contractions.
In order to record the timing of pain during contractions, it is
not sufficient to simply register uterine tone, since the correl-
ation between uterine tone and pain is highly variable.16 In
addition, standard external tocography yields a highly unreli-
able signal, and internal tocography is invasive and rarely avail-
able. A signal given by the parturient herself may indicate the
pain duration of a contraction more consistently. We had
tested a system where parturients registered the pain during
contractions by pressing a handheld dynamometer, since
handgrip force has been shown to correlate with descriptors
of pain intensity.17 A preliminary analysis had shown that
pain onset coincided well with the onset of contractions, but
that pain duration was often shorter than the duration of con-
tractions on the tocographic recording. Therefore, we used the
dynamometer data to calculate the mean duration of pain
during contractions. To generate time series of contractions,
however, which are calculated using the onset of contractions
only, the tocographic data are sufficient.
The results gathered in the first part of the study allowed us
to perform the mathematical modelling part. In this simula-
tion, we were able to show that a simple algorithm can
indeed predict the occurrence of future contractions quite
well, despite the observed irregularity.
Differences of simple moving average algorithms and the
complex ETS and ARIMA models are small in terms of the ac-
curacy of prediction. Both optimal ETS model and optimal
ARIMA model will eventually yield, through iterative refine-
ment of model parameters, the best forecasting model for a
specific labour data set. Nevertheless, the process being itera-
tive and needing several contraction intervals to bootstrap, it is
possible to obtain, in certain cases, suboptimal results com-
pared with more simple models.
Finally, if a three-point moving average forecast algorithm
of contractions is used, the mean remifentanil concentration
during a contraction, and especially at the beginning of a con-
traction, can be increased for most patients. This in turn
increases the efficacy of a remifentanil PCA. The average remi-
fentanil concentration in between two contractions, however,
is much less dependent on the timing of a bolus, and will be
only slightly lower when a remifentanil bolus is applied
before a (predicted) contraction. When considering this a
factor of the safety of a remifentanil PCA, even optimal bolus
application will not much improve safety. The finding from
our experimental data that pain during contractions is
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actually shorter than the duration of contractions estimated in
previous studies using tocographic recordings puts further
weight on the importance of inter-contraction remifentanil
concentration.
Our study is certainly limited by the fact that we only simu-
latedremifentanil bolus application and modelled remifentanil
concentrations using the pharmacokinetic–pharmacody-
namic model of Minto and colleagues.13 Since remifentanil
pharmacokinetics are linear,18 simulation is a valid way to
predict clinical scenarios. The Minto model is not very depend-
ent on age in the age range concerned byobstetrical analgesia.
It is based on lean body mass and thus independent of weight
gain during pregnancy. However, no pharmacokinetic–
pharmacodynamic studies exist for pregnant patients. In add-
ition, peak respiratory depression may arrive even later than
the peak remifentanil effect estimated by the model used.
Whereas the peak analgesic effect may coincide with the
peak effect predicted by the Minto model,19 peak respiratory
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Fig4 Comparison of the different modes of remifentanil bolus application (PCA, bolus is administered at the beginning of a contraction; BEST, bolus
is administered at the ideal time point to maximize efficacy; MEAN3, bolus is administered at the time point predicted by a three-point moving
average model; ETS, bolus is administered at the time point predicted by an ETS model) in terms of efficacy, safety, and effect-site concentration
at the beginning of pain during a contraction (‘instantaneous’). Shown are simulated mean effect-site concentrations for the four exemplary
patients with time series of more than 200 min. Box plots denote outliersmin ,Q1 21.5 IQR,Q1,Q2,Q3,Q3+1.5 IQR ,outliersmax with
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depression has been found to occurabout 2.5 min after a bolus,
and thus considerably later.20 Unfortunately, no pharmacoki-
netic–pharmacodynamic exists for respiratory depression,
and thus we were not able to simulate this important side-
effect directly.
In addition, the safety of a remifentanil PCA—improved by
prediction of future contraction and guided bolus application—
will not only be determined by average concentrations, but
also by those arriving at the outer limits of the probability dis-
tributions. The irregularity of inter-contraction intervals
observed in the experimental part of our study is large, and
thus from time to time, a bolus will be applied at a time when
no contraction will follow for several minutes (see examples
in Fig. 3), potentially leading to respiratory depression.
Recently, several cases of respiratory, cardiac arrest, or both
with the use of a remifentanil PCA during labour have been
reported,4 – 7 and editorials have discussed the safety of this al-
ternative to epidural analgesia during labour.1 21 Even if the ef-
ficacy of remifentanil PCA may be improved by optimized bolus
application, our simulations suggest that this would only have
a minimal impact on patient safety. Sedation is an important
warning sign of opioid overdose, and thus, we suggest that
optimized bolus application should never be used with auto-
matic bolus application. Instead, a signal (‘green light’) could
be given to the parturient, who will have to press the bolus
button herself. With this approach, the parturient stays in
total control of her analgesia, a factor known to influence
maternal satisfaction.22
However, remifentanil respiratory depression can occur very
fast, and thus sedation is not a sufficient warning sign.
One-to-one care by a midwife is recommended, and continu-
ous presence of a caregiver appears to be vital. In at least
two of the published case reports, the incident occurred
during a short absence of the midwife, underlining the import-
ance of a continuous presence of a caregiver.
It has also been suggested that remifentanil bolus calcula-
tion be based on lean body weight instead of actual weight.23
We have used actual weight for our simulations, since remi-
fentanil clearance in pregnant women at term has been
found to be rather increased,24 and actual dose should best
be titrated to effect to avoid under- and overdosing. Mucha-
tuta and Kinsella21 recommended in their editorial a 3 min
lockout to avoid a second bolus being given before the
maximum respiratory depression of a first bolus has been
attained. Considering our finding that even in first-stage
labour, the average interval between two contractions is
,3 min, a 3 min lockout will impede pain relief. Our results
suggest that optimizing bolus application by prediction of
future contraction may lead to a better overlap of pain and
remifentanil effect and thus improve safety. However, this
effect is small, and will not diminish the need of consequent
surveillance without interruptions.
In summary, we have shown, based on time series of painful
contractions during labour, that future contractions can be
predicted by a simple algorithm with sufficient precision to
improve the efficacy of remifentanil PCA during first-stage
labour. However, safety will only be improved slightly by
optimized bolus application, and thus, the need for safety mea-
sures will not be changed by this technique.
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